(Il Sole 24 Ore Radiocor) - Milano, 2 apr - Shares in Immunovant fell in premarket trading after the clinical-stage immunology company said studies of its batoclimab drug candidate in thyroid eye disease failed to meet their primary endpoint.

The North carolina-based company said patients in the studies demonstrated greater levels of proptosis improvement from baseline after the initial 12-week high-dose period than after the following 12-week low-dose period, supporting the benefit of deeper IgG suppression.

It said it will review future plans for the development of batoclimab with its partner, HanAll Biopharma, and will provide an update on the program in conjunction with HanAll at a future date.

At 1221 GMT Immunovant shares were down 6.2%.

(RADIOCOR) 02-04-26 14:29:27 (0383) 5 NNNN